The Genome Analysis Core (GAC or the Core) provides services, advice, and instrumentation for genotyping, gene expression, and epigenetic (methylation) analysis. Using two main platforms, the Sequenom MassArray and the AB 7900HT Real-Time QPCR instrument, the Core provides a variety of services at the low- to medium-throughput level important for understanding the genetics of cancer. Genotyping and mutation analyses of single nucleotide polymorphisms (SNPs) using the Sequenom MassArray are instrumental in helping scientists determine causative mutations in the germline or somatic genes, which lead to certain cancers or human diseases. Methylation analyses provided by the Sequenom MassArray assist in understanding the control of gene expression in tumor progression. A major focus of the Core's services is the use of quantitative real-time PCR (QPCR) on the 7900HT platform. Using a repository of TaqMan assays, the Core provides services for DNA copy number measurements, mRNA and miRNA expression analyses, plus training courses for members of the Helen Diller Family Comprehensive Cancer Center (Center) to learn QPCR techniques. Besides full-service options, most instrumentation is available for independent use by investigators The Center GAC works to improve access by Center members to genetic and genomic technologies. The services we offer, or propose to develop, are actively coordinated with the other UCSF genomics core facilities to avoid detrimental duplication of capacity. For example. Center members have access to extensive high throughput gene expression, genotyping, and sequencing technologies (Affymetrix and Illumina) through Core facilities at UCSF's Parnassus and Mission Bay campuses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388373
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$324,843
Indirect Cost
$117,386
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21

Showing the most recent 10 out of 192 publications